Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30577788 | 1.00 | IRAK4 (0.41) | IRAK4S1PR2S1PR4S1PR3HTR7 | |
| SCHEMBL13762868 | 0.86 | S1PR2 (0.41) | IRAK4S1PR2S1PR4S1PR3HTR7 | |
| SCHEMBL1022830 | 0.86 | S1PR2 (0.41) | IRAK4S1PR2S1PR4S1PR3HTR7 | |
| SCHEMBL2767058 | 0.84 | IRAK4 (0.38) | IRAK4S1PR2S1PR4S1PR3HTR7 | |
| SCHEMBL2036719 | 0.84 | IRAK4 (0.38) | IRAK4S1PR2S1PR4S1PR3HTR7 | |
| SCHEMBL14211421 | 0.84 | IRAK4 (0.38) | IRAK4S1PR2S1PR4S1PR3HTR7 | |
| SCHEMBL15447728 | 0.84 | IRAK4 (0.38) | IRAK4S1PR2S1PR4S1PR3HTR7 | |
| SCHEMBL18415006 | 0.84 | IRAK4 (0.38) | IRAK4S1PR2S1PR4S1PR3HTR7 | |
| SCHEMBL400366 | 0.84 | IRAK4 (0.38) | IRAK4S1PR2S1PR4S1PR3HTR7 | |
| SCHEMBL3465386 | 0.84 | IRAK4 (0.38) | IRAK4S1PR2S1PR4S1PR3HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735430-A1 | MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2026-05-06 | — | — | EP | disclosed |
| US-20250333405-A1 | ANTAGONISTS OF GPR39 PROTEIN | VASOCARDEA INC (US) | 2025-10-30 | — | — | US | disclosed |
| CN-115850263-B | 2, 7-Disubstituted benzothiazole compound and application thereof | 浙江工业大学 | 2025-06-17 | — | — | CN | disclosed |
| CN-115991721-B | Phosphine-containing compound, preparation method thereof and application of phosphine-containing compound as ligand of ethylene oligomerization catalyst composition | 中化学科学技术研究有限公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2025003414-A1 | MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-02 | — | — | WO | disclosed |
| EP-4423090-A2 | ANTAGONISTS OF GPR39 PROTEIN | Vasocardea, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-114787167-B | Compounds and compositions for the treatment of parasitic diseases | 诺华股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-11952374-B2 | Bicyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20090306016-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | UNIVERSITY OF CONNECTICUT | 2009-12-10 | — | — | US | disclosed |
| EP-2112173-A1 | Catalyst compounds and use thereof | ExxonMobil Chemical Patents Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| US-20090253750-A1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | ELI LILLY AND COMPANY | 2009-10-08 | — | — | US | disclosed |
| WO-2009123855-A1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | ELI LILLY AND COMPANY (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090233897-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
| US-20090197869-A1 | AZEPINE INHIBITORS OF JANUS KINASES | INCYTE CORPORATION, A DELAWARE CORPORATION | 2009-08-06 | — | — | US | disclosed |
| US-20090197869-A1 | AZEPINE INHIBITORS OF JANUS KINASES | INCYTE CORPORATION, A DELAWARE CORPORATION | 2009-08-06 | — | — | US | disclosed |
| US-7569589-B2 | Potassium channel inhibitors | MERCK & CO., INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | IRAK4 3359/4885S1PR2 1075/4885S1PR4 1242/4885 |
| US-11952374-B2 | Bicyclic compounds | SLC10A1, PKD1, CYP11B2 | IRAK4 4064/4885S1PR2 1585/4885S1PR4 2163/4885 |
| US-20090253750-A1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | CYP3A4, IPO4, JAK3 | IRAK4 314/4885S1PR2 2390/4885S1PR4 1023/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | IRAK4 2474/4885S1PR2 1173/4885S1PR4 1118/4885 |
| US-20090306016-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | FAAH, FAAH2, CNR2 | IRAK4 4378/4885S1PR2 1770/4885S1PR4 1818/4885 |
| US-20090197869-A1 | AZEPINE INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | IRAK4 147/4885S1PR2 1663/4885S1PR4 1257/4885 |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | CFD, TFPI, CFH | IRAK4 1849/4885S1PR2 925/4885S1PR4 889/4885 |
| US-20250333405-A1 | ANTAGONISTS OF GPR39 PROTEIN | GPR39, GPR139, GPR119 | IRAK4 2388/4885S1PR2 1452/4885S1PR4 2009/4885 |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | JAK1, JAK3, JAK2 | IRAK4 147/4885S1PR2 1663/4885S1PR4 1257/4885 |
| US-20090233897-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | IRAK4 3359/4885S1PR2 1075/4885S1PR4 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.